The m6A regulatory gene YTHDF3 alleviates acute pancreatitis by modulating CD45RA+ resting treg cells: A novel immunomodulatory biomarker

m6A调控基因YTHDF3通过调节CD45RA+静息Treg细胞缓解急性胰腺炎:一种新型免疫调节生物标志物

阅读:2

Abstract

Acute pancreatitis (AP) is an inflammatory disorder with a rising global incidence and substantial morbidity and mortality; however, its molecular pathogenesis remains unclear. Epigenetic regulation by N6-methyladenosine (m6A) RNA modification is increasingly being recognized as a key mechanism in immune and inflammatory diseases. However, the causal role of m6A-related genes and their immunological mediators in AP has not been elucidated. We performed 2-sample Mendelian randomization (MR) analysis to assess the causal relationship between m6A gene expression and AP risk using cis-eQTL data from the eQTLGen consortium and genome-wide association studies summary statistics from 855,309 individuals of European ancestry. Summary-data-based MR (SMR) and heterogeneity in dependent instruments tests were conducted to validate causality and to exclude linkage bias. Furthermore, a 2-step MR mediation analysis was performed using 612 immune cell traits from the Integrative Epidemiology Unit OpenGWAS database to identify downstream immune mediators. Among the 12 m6A genes with valid cis-eQTL instruments, only YTHDF3 demonstrated a significant protective effect against AP (OR = 0.876, 95% CI: 0.795-0.966, P = .0078). SMR analysis confirmed this association (b_SMR = -0.176, P = .0106) without evidence of heterogeneity (P_heterogeneity in dependent instruments = 0.451). Mediation analysis identified CD45RA+ resting regulatory T cells as a partial mediator of YTHDF3's effect (βa = 0.2758; β_b = -0.0297), with an indirect effect accounting for 6.18% of the total causal pathway. Our study identified YTHDF3 as a novel protective gene for AP and suggested that its effect is partially mediated by CD45RA+ resting Treg cells. These findings reveal a previously unrecognized m6A-immune axis and offer potential biomarkers and targets for immunomodulatory interventions in AP.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。